{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:10:18Z","timestamp":1791277818511,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":2593,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Excellentie Financiering KU Leuven","award":["EF\/05\/013"],"award-info":[{"award-number":["EF\/05\/013"]}]},{"name":"Programma Financiering KU Leuven","award":["PF\/10\/014"],"award-info":[{"award-number":["PF\/10\/014"]}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1111\/jth.13138","type":"journal-article","created":{"date-parts":[[2015,9,8]],"date-time":"2015-09-08T04:32:55Z","timestamp":1441686775000},"page":"2087-2092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders"],"prefix":"10.1016","volume":"13","author":[{"given":"M.","family":"Jacquemin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Toelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schoeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"van Horenbeeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Vanlinthout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Debasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Peetermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Vanassche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Peerlinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"van Ryn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13138_bb0010","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double\u2010blind, non\u2010inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/jth.13138_bb0015","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13138_bb0020","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13138_bb0025","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13138_bb0030","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate \u2013 a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13138_bb0035","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00228-013-1550-4","article-title":"Evaluation of coagulation assays versus LC\u2010MS\/MS for determinations of dabigatran concentrations in plasma","volume":"69","author":"Antovic","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jth.13138_bb0040","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1160\/TH13-03-0202","article-title":"Comparison of calibrated dilute thrombin time and aPTT tests with LC\u2010MS\/MS for the therapeutic monitoring of patients treated with dabigatran etexilate","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13138_bb0045","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/jth.12308","article-title":"Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross\u2010sectional pharmacodynamic study based on peak and trough plasma levels","volume":"11","author":"Hawes","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13138_bb0050","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/MBC.0000000000000056","article-title":"Dabigatran assessment in patients with acute complications using routine coagulation assays","volume":"25","author":"Stang","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.13138_bb0055","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1160\/TH14-09-0808","article-title":"Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays","volume":"113","author":"Douxfils","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13138_bb0060","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.13138_bb0065","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo\u2010controlled, double\u2010blind phase 1 trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet"},{"key":"10.1111\/jth.13138_bb0070","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13138_bb0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE\u2010LY Trial (Randomized Evaluation of Long\u2010Term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.13138_bb0080","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH10-06-0342","article-title":"Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays","volume":"105","author":"Lindahl","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13138_bb0085","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","article-title":"Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate","volume":"107","author":"Douxfils","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13138_bb0090","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bjh.12052","article-title":"Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology","volume":"159","author":"Baglin","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13138_bb0095","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1345\/aph.1R179","article-title":"Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicentre, in vitro study","volume":"46","author":"Dager","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1111\/jth.13138_bb0100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1309\/AJCPY6G6ZITVKPVH","article-title":"The effect of dabigatran on select specialty coagulation assays","volume":"139","author":"Adcock","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/jth.13138_bb0105","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1373\/clinchem.2012.198788","article-title":"Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories","volume":"59","author":"Helin","year":"2013","journal-title":"Clin Chem"},{"key":"10.1111\/jth.13138_bb0110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1160\/TH14-02-0161","article-title":"Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey","volume":"113","author":"van Blerk","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13138_bb0115","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinternmed.2011.314","article-title":"The use of dabigatran in elderly patients","volume":"171","author":"Legrand","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1111\/jth.13138_bb0120","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/eurheartj\/eht310.P4848","article-title":"Reversal of dabigatran clotting activity in the rat ex vivo by a specific and selective antibody fragment antidote: are there non\u2010specific effects on warfarin, rivaroxaban and apixaban?","volume":"34","author":"van Ryn","year":"2013","journal-title":"Eur Heart J"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13138","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13138","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622086950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622086950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13138\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:09:17Z","timestamp":1761534557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622086950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1538783622086950"],"URL":"https:\/\/doi.org\/10.1111\/jth.13138","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}